In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species

Detalhes bibliográficos
Autor(a) principal: Bernardes,Ana Catharina Fernandes Pereira Ferreira
Data de Publicação: 2019
Outros Autores: Coelho,Grazielle Brandão, Araújo,Marcela Carolina de Paula Michel, Saúde-Guimarães,Dênia Antunes
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Brasileira de Farmacognosia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2019000200241
Resumo: ABSTRACT Hyperuricemia is the main cause of gout, an inflammation induced by uric acid deposition in joints. Drugs available present side effects, so there is a need for new treatment alternatives. Lychnophora species are used in folk medicine to treat inflammation, rheumatism and muscle pain. Goyazensolide (10 mg/kg), eremantholide C (25 mg/kg) and lychnopholide (25 mg/kg), sesquiterpene lactones isolated from Lychnophora species were previously studied and showed anti-hyperuricemic effects in mice. However, the mechanisms of this effect were not elucidated. The methodology of this study consisted in treatment of hyperuricemic-induced rats, and comparison between control groups, clinically used anti-hyperuricemic drugs and sesquiterpene lactones. Urine and blood were collected for uric acid quantification. Xanthine oxidase inhibition was measured in liver homogenates. Results showed that all evaluated sesquiterpene lactones presented anti-hyperuricemic activity at the doses of 5 and 10 mg/kg and can act through one or both mechanisms, depending on the dose administrated. Goyazensolide and lychnopholide at dose of 5 mg/kg showed important uricosuric effect. Goyazensolide and lychnopholide at dose of 10 mg/kg, and eremantholide C (5 and 10 mg/kg) presented notable inhibition of hepatic xanthine oxidase activity and uricosuric effect. Thus, these sesquiterpene lactones are promising hypouricemic agent to treat hyperuricemia and gout.
id SBFGNOSIA-1_d1cfee0dfc374de449fac622221e057d
oai_identifier_str oai:scielo:S0102-695X2019000200241
network_acronym_str SBFGNOSIA-1
network_name_str Revista Brasileira de Farmacognosia (Online)
repository_id_str
spelling In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora speciesSesquiterpene lactonesHyperuricemiaXanthine oxidaseUricosuric effectGoutABSTRACT Hyperuricemia is the main cause of gout, an inflammation induced by uric acid deposition in joints. Drugs available present side effects, so there is a need for new treatment alternatives. Lychnophora species are used in folk medicine to treat inflammation, rheumatism and muscle pain. Goyazensolide (10 mg/kg), eremantholide C (25 mg/kg) and lychnopholide (25 mg/kg), sesquiterpene lactones isolated from Lychnophora species were previously studied and showed anti-hyperuricemic effects in mice. However, the mechanisms of this effect were not elucidated. The methodology of this study consisted in treatment of hyperuricemic-induced rats, and comparison between control groups, clinically used anti-hyperuricemic drugs and sesquiterpene lactones. Urine and blood were collected for uric acid quantification. Xanthine oxidase inhibition was measured in liver homogenates. Results showed that all evaluated sesquiterpene lactones presented anti-hyperuricemic activity at the doses of 5 and 10 mg/kg and can act through one or both mechanisms, depending on the dose administrated. Goyazensolide and lychnopholide at dose of 5 mg/kg showed important uricosuric effect. Goyazensolide and lychnopholide at dose of 10 mg/kg, and eremantholide C (5 and 10 mg/kg) presented notable inhibition of hepatic xanthine oxidase activity and uricosuric effect. Thus, these sesquiterpene lactones are promising hypouricemic agent to treat hyperuricemia and gout.Sociedade Brasileira de Farmacognosia2019-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2019000200241Revista Brasileira de Farmacognosia v.29 n.2 2019reponame:Revista Brasileira de Farmacognosia (Online)instname:Sociedade Brasileira de Farmacognosia (SBFgnosia)instacron:SBFGNOSIA10.1016/j.bjp.2018.12.008info:eu-repo/semantics/openAccessBernardes,Ana Catharina Fernandes Pereira FerreiraCoelho,Grazielle BrandãoAraújo,Marcela Carolina de Paula MichelSaúde-Guimarães,Dênia Antuneseng2019-05-21T00:00:00Zoai:scielo:S0102-695X2019000200241Revistahttp://www.sbfgnosia.org.br/revista/https://old.scielo.br/oai/scielo-oai.phprbgnosia@ltf.ufpb.br1981-528X0102-695Xopendoar:2019-05-21T00:00Revista Brasileira de Farmacognosia (Online) - Sociedade Brasileira de Farmacognosia (SBFgnosia)false
dc.title.none.fl_str_mv In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species
title In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species
spellingShingle In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species
Bernardes,Ana Catharina Fernandes Pereira Ferreira
Sesquiterpene lactones
Hyperuricemia
Xanthine oxidase
Uricosuric effect
Gout
title_short In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species
title_full In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species
title_fullStr In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species
title_full_unstemmed In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species
title_sort In vivo anti-hyperuricemic activity of sesquiterpene lactones from Lychnophora species
author Bernardes,Ana Catharina Fernandes Pereira Ferreira
author_facet Bernardes,Ana Catharina Fernandes Pereira Ferreira
Coelho,Grazielle Brandão
Araújo,Marcela Carolina de Paula Michel
Saúde-Guimarães,Dênia Antunes
author_role author
author2 Coelho,Grazielle Brandão
Araújo,Marcela Carolina de Paula Michel
Saúde-Guimarães,Dênia Antunes
author2_role author
author
author
dc.contributor.author.fl_str_mv Bernardes,Ana Catharina Fernandes Pereira Ferreira
Coelho,Grazielle Brandão
Araújo,Marcela Carolina de Paula Michel
Saúde-Guimarães,Dênia Antunes
dc.subject.por.fl_str_mv Sesquiterpene lactones
Hyperuricemia
Xanthine oxidase
Uricosuric effect
Gout
topic Sesquiterpene lactones
Hyperuricemia
Xanthine oxidase
Uricosuric effect
Gout
description ABSTRACT Hyperuricemia is the main cause of gout, an inflammation induced by uric acid deposition in joints. Drugs available present side effects, so there is a need for new treatment alternatives. Lychnophora species are used in folk medicine to treat inflammation, rheumatism and muscle pain. Goyazensolide (10 mg/kg), eremantholide C (25 mg/kg) and lychnopholide (25 mg/kg), sesquiterpene lactones isolated from Lychnophora species were previously studied and showed anti-hyperuricemic effects in mice. However, the mechanisms of this effect were not elucidated. The methodology of this study consisted in treatment of hyperuricemic-induced rats, and comparison between control groups, clinically used anti-hyperuricemic drugs and sesquiterpene lactones. Urine and blood were collected for uric acid quantification. Xanthine oxidase inhibition was measured in liver homogenates. Results showed that all evaluated sesquiterpene lactones presented anti-hyperuricemic activity at the doses of 5 and 10 mg/kg and can act through one or both mechanisms, depending on the dose administrated. Goyazensolide and lychnopholide at dose of 5 mg/kg showed important uricosuric effect. Goyazensolide and lychnopholide at dose of 10 mg/kg, and eremantholide C (5 and 10 mg/kg) presented notable inhibition of hepatic xanthine oxidase activity and uricosuric effect. Thus, these sesquiterpene lactones are promising hypouricemic agent to treat hyperuricemia and gout.
publishDate 2019
dc.date.none.fl_str_mv 2019-04-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2019000200241
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2019000200241
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.bjp.2018.12.008
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Farmacognosia
publisher.none.fl_str_mv Sociedade Brasileira de Farmacognosia
dc.source.none.fl_str_mv Revista Brasileira de Farmacognosia v.29 n.2 2019
reponame:Revista Brasileira de Farmacognosia (Online)
instname:Sociedade Brasileira de Farmacognosia (SBFgnosia)
instacron:SBFGNOSIA
instname_str Sociedade Brasileira de Farmacognosia (SBFgnosia)
instacron_str SBFGNOSIA
institution SBFGNOSIA
reponame_str Revista Brasileira de Farmacognosia (Online)
collection Revista Brasileira de Farmacognosia (Online)
repository.name.fl_str_mv Revista Brasileira de Farmacognosia (Online) - Sociedade Brasileira de Farmacognosia (SBFgnosia)
repository.mail.fl_str_mv rbgnosia@ltf.ufpb.br
_version_ 1752122471126925312